(PDF) Natalizumab for Relapsing-Remitting Ms in the Uk Top

Natalizumab for Relapsing-Remitting Ms in the Uk Top Cohort

Journal of Neurology, Neurosurgery and Psychiatry - United Kingdom

doi 10.1136/jnnp-2014-309236.137

Full Text

Abstract

Available in full text

Categories

Date

September 9, 2014

Authors

Richard Nicholas

Publisher

BMJ

Related search

Natalizumab: A New Treatment for Relapsing Remitting Multiple Sclerosis

Therapeutics and Clinical Risk Management

Chemical Health

Safety Research

English

Endocarditis Following Ocrelizumab in Relapsing-Remitting MS

Neurology: Neuroimmunology and NeuroInflammation

English

Real-Life Effectiveness of Natalizumab in Relapsing-Remitting Multiple Sclerosis (Rrms): A Registry Analysis

Value in Health

Occupational Health

English

Pnd12 - Natalizumab Versus Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis

Value in Health

Occupational Health

English

Efficacy of Natalizumab and Fingolimod in Relapsing Remitting Multiple Sclerosis in Real World Clinical Setting

Journal of Neurology & Neurophysiology

English

Acute Effects of Alemtuzumab Infusion in Patients With Active Relapsing-Remitting MS

Neurology: Neuroimmunology and NeuroInflammation

English

Long-Term Safety and Efficacy of Natalizumab in Relapsing-Remitting Multiple Sclerosis: Impact on Quality of Life

Patient Related Outcome Measures

English

Long-Term Evaluation of NEDA-3 Status in Relapsing-Remitting Multiple Sclerosis Patients After Switching From Natalizumab to Fingolimod

Therapeutic Advances in Neurological Disorders

English

Remitting–relapsing Multiple Sclerosis Patient Refractory to Conventional Treatments and Bone Marrow Transplantation Who Responded to Natalizumab

International Journal of General Medicine

English